Literature DB >> 1621876

Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men.

N Geary1, H R Kissileff, F X Pi-Sunyer, V Hinton.   

Abstract

Pancreatic glucagon and cholecystokinin octapeptide (CCK-8) were intravenously infused (1 ml/min for 10 min) alone or in combination beginning 15 min after normal-weight men had eaten a 500-ml tomato soup preload and 5 min before they were served a lunch of macaroni and beef with tomato sauce. Infusion of approximately 3 ng.kg-1.min-1 glucagon or approximately 2 ng.kg-1.min-1 CCK-8 each reduced test meal size. However, simultaneous infusion of these peptide doses reduced meal size less than the sum of the peptides' individual effects. Infusions of approximately 1.5 ng.kg-1.min-1 glucagon or approximately 1 ng.kg-1.min-1 CCK-8 had neither individual nor interactive effects on meal size. Psychophysical ratings failed to detect nonspecific side effects after any of the infusions. That exogenous glucagon and CCK-8 each reduced meal size without side effects suggests that these peptides may participate in the physiological control of human appetite; that their simultaneous infusion resulted in an infra-additive reduction in meal size suggests that they can interact antagonistically.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1621876     DOI: 10.1152/ajpregu.1992.262.6.R975

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  38 in total

1.  Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.

Authors:  Emilie Bahne; Emily W L Sun; Richard L Young; Morten Hansen; David P Sonne; Jakob S Hansen; Ulrich Rohde; Alice P Liou; Margaret L Jackson; Dayan de Fontgalland; Philippa Rabbitt; Paul Hollington; Luigi Sposato; Steven Due; David A Wattchow; Jens F Rehfeld; Jens J Holst; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Minireview: Glucagon in stress and energy homeostasis.

Authors:  B J Jones; T Tan; S R Bloom
Journal:  Endocrinology       Date:  2012-01-31       Impact factor: 4.736

Review 3.  Bowels control brain: gut hormones and obesity.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Nat Rev Endocrinol       Date:  2010-06-29       Impact factor: 43.330

Review 4.  Intestinal GLP-1 and satiation: from man to rodents and back.

Authors:  R E Steinert; C Beglinger; W Langhans
Journal:  Int J Obes (Lond)       Date:  2015-08-28       Impact factor: 5.095

5.  Glucagon regulates orexin A secretion in humans and rodents.

Authors:  Ayman M Arafat; Przemysław Kaczmarek; Marek Skrzypski; Ewa Pruszyńska-Oszmałek; Paweł Kołodziejski; Aikaterini Adamidou; Stephan Ruhla; Dawid Szczepankiewicz; Maciej Sassek; Maria Billert; Bertram Wiedenmann; Andreas F H Pfeiffer; Krzysztof W Nowak; Mathias Z Strowski
Journal:  Diabetologia       Date:  2014-07-27       Impact factor: 10.122

Review 6.  Pancreatic signals controlling food intake; insulin, glucagon and amylin.

Authors:  Stephen C Woods; Thomas A Lutz; Nori Geary; Wolfgang Langhans
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 7.  Emerging combinatorial hormone therapies for the treatment of obesity and T2DM.

Authors:  Sharon A Sadry; Daniel J Drucker
Journal:  Nat Rev Endocrinol       Date:  2013-03-12       Impact factor: 43.330

Review 8.  The alpha-cell as target for type 2 diabetes therapy.

Authors:  Mikkel Christensen; Jonatan I Bagger; Tina Vilsbøll; Filip K Knop
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 9.  Glucagon action in the brain.

Authors:  Mona A Abraham; Tony K T Lam
Journal:  Diabetologia       Date:  2016-04-26       Impact factor: 10.122

10.  Appetite-Related Gut Peptides in Obesity and Binge Eating Disorder.

Authors:  Allan Geliebter; Christopher N Ochner; Roni Aviram-Friedman
Journal:  Am J Lifestyle Med       Date:  2008-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.